MS-Tagged Probe Linkers for In Vivo Multiplex Biomarker Quantification

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for quantifying protein receptors in cancer cells are limited by interference and degradation of biological material, and cannot be used in vivo to detect or quantify biomarkers in their natural environment, allowing for only non-quantitative detection of up to 4 biomarkers per cycle.

Innovation Solution

The use of MS-tagged probes with a cleavable iminosydnone linker through a click-and-release bioorthogonal reaction, allowing for multiplexed analysis of biomarkers in vivo by administering the probes, which are released in physiological fluids for quantification.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If cyclic immunofluorescence with fluorescent antibodies is used, then multiple biomarkers can be detected through repeated cycles, but the biological material degrades and interference increases with each cycle

Engineering Contradiction:
Improvenumber of detection cyclesVSAvoidquality of biological material
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The fluorescent label is extracted and removed from the antibody after detection, allowing the antibody to be reused for additional detection cycles without degradation from repeated fluorescent staining and bleaching processes

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The method replaces the optical detection system (fluorescence microscopy) with a mass spectrometry-based detection system that quantifies antibodies bound to biomarkers through MS signal intensity, eliminating the need for fluorescent labeling and its associated degradation issues

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Quantity of substance

If immunofluorescence devices are used for biomarker detection, then up to 4 biomarkers can be detected per cycle, but the results are not quantitative and tissue removal is required

Engineering Contradiction:
Improvenumber of biomarkers detectedVSAvoidquantification accuracy
Core Design Contradiction:
Quantity of substanceVSMeasurement precision

Solution Approach 1:

The patent replaces qualitative immunofluorescence imaging with quantitative mass spectrometry detection, where the MS signal intensity directly correlates with the amount of antibody-bound biomarker, enabling precise quantification of multiple biomarkers simultaneously

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The mass spectrometry-based platform can detect and quantify any number of biomarkers limited only by the panel of antibodies used, rather than being restricted to 4 biomarkers per cycle as in immunofluorescence, while also providing quantitative measurement capability

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If harsh chemical agents or photobleaching are used to inactivate fluorophores, then fluorescence can be erased for new cycles, but biological material degradation and interference increase

Engineering Contradiction:
Improvereusability of detection systemVSAvoiddamage to biological material
Core Design Contradiction:
Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

Instead of using harsh chemicals or photobleaching to inactivate fluorophores, the method extracts and removes the fluorescent label from the antibody through chemical cleavage, allowing the antibody to be recovered and reused without exposing the biological material to degrading conditions

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

A cleavable linker acts as an intermediary between the fluorescent label and the antibody, allowing controlled release of the fluorophore without requiring harsh treatment of the antibody or biological material, thus preserving material integrity across multiple cycles

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables the characterization of tumors in their native environment with multiplexed analysis of multiple biomarkers, allowing for infinite cycles of detection and quantification without tissue removal, and provides a valuable tool for tumor characterization and therapy selection.

Implementation Method 1

click-and-release bioorthogonal reaction involving an iminosydnone linker

Methodology Applied
Scientific EffectClick chemistry: Chemical Bonding

Implementation Method 2

click-and-release bioorthogonal reaction involving an iminosydnone linker

Methodology Applied
Scientific EffectBioorthogonal reaction: Chemical Bonding

Implementation Method 3

Detecting, by mass spectrometry, the nature and optionally the amount of the released MS-tags

Methodology Applied
Scientific EffectMass spectrometry:

Data Source

PatentEP4667939A1Multiplex cancer cell profiling using ms-tagged probes containing an iminosydnone cleavable linker
Publication Date: 2025.12.24 COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
  • EP4667939A1 patent drawingFigure 1A~1B
  • EP4667939A1 patent drawingFigure 2~3
  • EP4667939A1 patent drawingFigure 4~5A

AI summary

The accurate quantification of biomarkers is paramount in modern medicine, particularly in cancer where precise diagnosis is imperative for targeted therapy selection. There is therefore a long felt need for techniques using cell surface specific agents that can be used for identifying cancerous tissue and therefore the need for cell surface specific biomarkers. In this context, the present invention proposes performant multiplexed analysis methods using probes linked to cleavable MS-tag isotopologues by a click-and-release bioorthogonal reaction involving an iminosydnone linker. The great potential of this approach is herein demonstrated in culture cells, in tissues as well as in vivo, thereby unveiling promising diagnostic avenues, especially for cancer cell immunoprofiling.